Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ardmore Shipping Corporation engages in the seaborne transportation of petroleum products and chemicals worldwide. As of February 15, 2022, the company operated a fleet of 25 double-hulled product and chemical tankers. It serves oil majors, oil companies, oil and chemical traders, chemical companies, and pooling service providers. The company was founded in 2010 and is based in Pembroke, Bermuda.

Ardmore Shipping Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HAMILTON, BERMUDA, JULY 29, 2026 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE", THE "COMPANY" OR "WE") TODAY ANNOUNCED RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE30,2026. HIGHLIGHTS AND RECENT ACTIVITY REPORTED NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $60.5 MILLION FOR THE THREE MONTHS ENDED JUNE30,2026, OR $1.48 EARNINGS PER BASIC AND DILUTED SHARE, COMPARED TO NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $9.0 MILLION, OR $0.22 EARNINGS PER BASIC AND DILUTED SHARE FOR THE THREE MONTHS ENDED JUNE30,2025.

ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026

HAMILTON, BERMUDA, JULY 22, 2026 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE" OR THE "COMPANY") TODAY ANNOUNCED THAT THE COMPANY PLANS TO ANNOUNCE ITS SECOND QUARTER EARNINGS BEFORE THE MARKET OPENS ON WEDNESDAY, JULY 29, 2026 AND WILL HOST A CONFERENCE CALL LATER IN THE DAY AT 10:00 A.M. EASTERN TIME.

ARDMORE SHIPPING ANNOUNCES SECOND QUARTER 2026 CONFERENCE CALL AND WEBCAST

CHICAGO & MILPITAS, CALIF.--(BUSINESS WIRE)--SYNTAX BIO, A SYNTHETIC BIOLOGY COMPANY PROGRAMMING THE NEXT GENERATION OF CELL THERAPIES, AND APPLIED STEMCELL CORP. (ASC), A LEADER IN INDUCED PLURIPOTENT STEM CELL (IPSC) TECHNOLOGY AND GENOME ENGINEERING, TODAY ANNOUNCED A STRATEGIC COLLABORATION TO HELP UNLOCK THE NEXT GENERATION OF REGENERATIVE MEDICINE. THE COLLABORATION WILL FOCUS ON EVALUATING ASC'S IPSC AND HYPOIMMUNE CELL LINES USING SYNTAX BIO'S PROPRIETARY CELLGORITHM PLATFORM TO ADVANC.

SYNTAX BIO AND APPLIED STEMCELL ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE STEM CELL INNOVATION

HAMILTON, BERMUDA, JUNE 16, 2026 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE" OR THE "COMPANY") TODAY ANNOUNCED IT HAS EXERCISED THE OPTIONS FOR TWO ADDITIONAL 40,500 DWT HANDYSIZE PRODUCT/CHEMICAL TANKERS TO BE BUILT AT WUHU SHIPYARD, THEREBY EXPANDING THE ORIGINAL ORDER TO FOUR VESSELS IN TOTAL ON THE SAME TERMS. THE DELIVERIES OF THESE FOUR VESSELS ARE SCHEDULED FROM LATE 2028 AND ONWARDS.

ARDMORE SHIPPING EXERCISES NEWBUILDING OPTIONS

HAMILTON, BERMUDA, MAY 7, 2026 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE", THE "COMPANY" OR "WE") TODAY ANNOUNCED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026. HIGHLIGHTS AND RECENT ACTIVITY REPORTED ADJUSTED EARNINGS AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $23.6 MILLION FOR THE THREE MONTHS ENDED MARCH 31, 2026, OR $0.58 ADJUSTED EARNINGS PER BASIC AND DILUTED SHARE, COMPARED TO ADJUSTED EARNINGS AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $5.6 MILLION, OR $0.14 ADJUSTED EARNINGS PER BASIC AND DILUTED SHARE FOR THE THREE MONTHS ENDED MARCH 31, 2025.

ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026

HAMILTON, BERMUDA, APRIL 29, 2026 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE" OR THE "COMPANY") TODAY ANNOUNCED THAT THE COMPANY PLANS TO ANNOUNCE ITS FIRST QUARTER EARNINGS BEFORE THE MARKET OPENS ON THURSDAY, MAY 7, 2026 AND WILL HOST A CONFERENCE CALL LATER IN THE DAY AT 10:00 A.M. EASTERN TIME.

ARDMORE SHIPPING ANNOUNCES FIRST QUARTER 2026 CONFERENCE CALL AND WEBCAST

SIGNED CONTRACTS FOR THE CONSTRUCTION OF TWO OPTION TWO 40,500 DWT IMO2 PRODUCT/CHEMICAL TANKERS DOUBLING DIVIDEND PAYOUT RATIO TO TWO-THIRDS OF ADJUSTED EARNINGS, EFFECTIVE 1Q 2026 AGREED SALE OF ONE 2014-BUILT MR TANKER FOR $35.5 MILLION WITH JUNE DELIVERY MR SPOT TCES OF $33,700 PER DAY FOR 1Q 2026 AND FIXED $50,000 PER DAY IN 2Q 2026 TO-DATE HAMILTON, BERMUDA, APRIL 29, 2026 /PRNEWSWIRE/ --ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE" OR THE "COMPANY") TODAY PROVIDED THE FOLLOWING UPDATE ON CAPITAL ALLOCATION, VESSEL SALE, AND LATEST TCE GUIDANCE. FLEET INVESTMENT THE COMPANY SIGNED CONTRACTS FOR THE CONSTRUCTION OF TWO HIGHLY-EFFICIENT AND VERSATILE 40,500 DWT HANDYSIZE PRODUCT/CHEMICAL TANKERS AT WUHU SHIPYARD, AT A PRICE OF $44.9 MILLION PER VESSEL, INCLUSIVE OF APPROXIMATELY $3 MILLION FOR FULL IMO2 SPECIFICATION AND MARINELINE TANK COATINGS.

ARDMORE SHIPPING PROVIDES UPDATE ON FLEET INVESTMENT, DIVIDEND POLICY, AND VESSEL SALE

- 13-WEEK U.S. PHASE II STUDY IS EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL SMALL MOLECULE GLP-1R AGONIST ASC30, A ONCE-DAILY TABLET, IN 100 PARTICIPANTS WITH DIABETES. - TOPLINE DATA FROM THE PHASE II STUDY ARE EXPECTED IN THE THIRD QUARTER OF 2026.

ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OF ASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THE TREATMENT OF DIABETES

-FIXED - DOSE COMBINATION OF ASC30 AND ASC39 (ASC30_39 FDC) TABLETS, DOSED ORALLY IN DOGS, DEMONSTRATED COMPARABLE PHARMACOKINETICS TO THOSE OBSERVED IN THEIR RESPECTIVE MONOTHERAPIES IN A HEAD-TO-HEAD STUDY . THE FIXED DOSE COMBINATION HAD EXCELLENT ORAL BIOAVAILABILITY, DRUG EXPOSURE AND A HALF -LIFE OF UP TO 12 HOURS.

ASCLETIS ANNOUNCES FIXED-DOSE COMBINATION OF ASC30, ONCE-DAILY ORAL SMALL MOLECULE GLP-1R AGONIST, AND ASC39, ONCE-DAILY ORAL SMALL MOLECULE AMYLIN-SELECTIVE AMYLIN RECEPTOR AGONIST, FOR CLINICAL DEVELOPMENT

ZYVERSA IS ADVANCING A HIGHLY DIFFERENTIATED PIPELINE FOCUSING ON INFLAMMATORY AND RENAL DISEASES WITH A TOTAL ACCESSIBLE MARKET >$100 BILLION. INFLAMMASOME ASC INHIBITOR IC 100 IS A NEXT GENERATION DRUG DESIGNED FOR UNPARALLELED CONTROL OF DISEASE-CAUSING INFLAMMATION BY (1) INHIBITING MULTIPLE INFLAMMASOMES ACTIVATED IN NUMEROUS DISEASES, NOT JUST NLRP3, AND (2) ATTENUATING SPREAD AND PERPETUATION OF INFLAMMATION BY UNIQUELY INHIBITING ASC SPECKS.

Ardmore Shipping Corporation

ASC

Price

Financial Reports

No items found.

Press Releases

Ardmore Shipping Corporation

ASC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ASC